On the stock market since 2021, it operates in the world of health and science. It has 2,960 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 19% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 19% a year on average.
Sales run at $337.6M a year. A small number, but proof the product has real buyers.
There is $38.8M in the vault; even if every debt were paid off, $38.3M would remain.
A loss of $10.0M against $337.6M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, CNVY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CNVY is a high-risk stock — not yet profitable, and its future rides on its product catching on.